May. 3 at 4:59 AM
$MLTX $ORKA
Orka-002 is essentially Brimzelx modified for a long half life of about 100 days.
The primary difference lies in the Fc region of the antibody. ORKA-002 uses a specific set of amino acid substitutions known as "YTE" modifications. These modifications increase the antibody's ability to "recycle" itself within the body rather than being broken down.
Without these specific YTE changes, the remaining protein sequence of ORKA-002 is engineered to mirror the bimekizumab while providing Oruka with its own proprietary molecule to bypass patent laws.
The problem is Brimzelx has severe FDA warnings on usage which can be overcome because of its short half life. ORKA-002 can not.
The existing clinical trials on ORKA-002 omitted 95% of the patients needing these drugs.
I have a very strong opinion that ORKA-002 will not pass the phase 3 trials because of the harm a monoclonal Brimzelx with an extended half life can cause; especially suicides!
The new medicine is NanoBody SLK.
